Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182866 · ClinicalTrials.gov registry record · Phase 2
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
A Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by Rakuten Medical.
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT05182866: Active Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by Rakuten Medical.
NCT05182866 is a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck that is active but no longer recruiting, run by Rakuten Medical. The registered enrollment target is 9 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05182866, a Phase 2 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, is active but no longer recruiting, sponsored by Rakuten Medical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Conditions Studied
Interventions
- COMBINATION_PRODUCT ASP-1929 Photoimmunotherapy
Study Locations (1)
Maryland
- Center for Cancer Research - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT05182866 still lists
NCT05182866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which ASP-1929 Photoimmunotherapy is the first listed.
NCT05182866 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05182866 about?
NCT05182866 is a clinical study titled "ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer". A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
What is the current status of trial NCT05182866?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2022-01-21. Estimated completion is 2026-06-30.
What conditions does trial NCT05182866 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT05182866?
The interventions under investigation include: ASP-1929 Photoimmunotherapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05182866?
This trial is sponsored by Rakuten Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05182866 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05182866's enrollment target sits among peer trials
9 239th of 250 higher than 12 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Panitumumab-IRDye800 in Head & Neck Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI